ライフサイエンスコーパス: occult blood test

1 o screening with biennial guaiac-based fecal occult blood test.

2 onoscopy, serum CEA, punch biopsy and Faecal occult blood test.

3 the sensitivity and specificity of the fecal occult blood test.

4 etter performance characteristics than fecal occult blood tests.

5 ged 80-84 years in average health with fecal occult blood tests.

6 nal bleeding, as evidenced by positive fecal occult blood tests.

7 ears to be lower than that with guaiac fecal occult blood testing.

8 aou smears, cholesterol screening, and fecal occult blood testing.

9 y exists for widespread screening with fecal occult blood testing.

10 elevant to optimizing the technique of fecal occult blood testing.

11 r to annual or biennial screening with fecal occult-blood testing.

12 tion of hematochezia (19%) or positive fecal occult blood test (15%).

13 40%), blood glucose measurement (41%), fecal occult blood testing (39%), and chest radiography (36%),

14 78 healthy women aged 70-74 years with fecal occult blood tests, 431 women aged 75-79 years in poor h

15 reening, 2) FIT: annual immunochemical fecal occult blood test age 40-75 years, 3) gFOBT: annual guai

16 5 years, 3) gFOBT: annual guaiac-based fecal occult blood test age 40-75 years, and 4) COL: 10-yearly

17 reasonable substitutes for traditional fecal occult blood testing, although modeling may be needed to

18 ical smear test, 2) a mammogram, 3) a faecal occult blood test and 4) a prostate specific antigen tes

19 ded to improve patient compliance with fecal occult blood testing and colorectal cancer screening in

20 d clinical trials to reduce mortality: fecal occult blood testing and flexible sigmoidoscopy.

21 Combining fecal occult blood testing and sigmoidoscopy may decrease mort

22 s likely than nonphysicians to undergo fecal occult blood testing and were more likely to undergo col

23 Combined one-time screening with a fecal occult-blood test and sigmoidoscopy identified 75.8 perc

24 Fecal occult-blood testing and sigmoidoscopy have been recomme

25 returned the three specimen cards for fecal occult-blood testing and underwent a complete colonoscop

26 ge-matched men and women with negative fecal occult-blood tests and no family history of colon cancer

27 ed trials support the use of screening fecal occult blood testing, and case-control studies support t

28 erred for colonoscopy with a positive faecal occult blood test as part of the UK national bowel cance

29 rs (for example, simplifying access to fecal occult blood test cards), or made system-level changes (

30 anol, RNAlater Stabilization Solution, fecal occult blood test cards, and fecal immunochemical test t

31 The stool occult blood test continues to be utilized for reasons o

32 sting or high-sensitivity guaiac-based fecal occult blood testing every 2 years, colonoscopy every 10

33 d with sigmoidoscopy every 5 years and fecal occult blood testing every year (FS/FOBT) or colonoscopy

34 Screening with sensitive guaiac-based fecal occult blood testing, fecal immunochemical testing (FIT)

35 favorably with reported performance of fecal occult blood testing, flexible sigmoidoscopy, and barium

36 alth status using 3 strategies: annual fecal occult blood tests, flexible sigmoidoscopy every 5 years

37 ry care providers use only the digital fecal occult blood test (FOBT) as their primary screening test

38 screened, the use of high-sensitivity fecal occult blood test (FOBT) decreased between 2011 and 2019

39 ing test for colorectal neoplasia; the fecal occult blood test (FOBT) detects neoplasias with low lev

40 y compared three screening modalities: Fecal Occult Blood Test (FOBT) followed by colonoscopy or sigm

41 The use of the fecal occult blood test (FOBT) for colorectal cancer (CRC) scr

42 as average risk, suggesting the use of fecal occult blood test (FOBT) instead of colonoscopy.

43 The Fecal Occult Blood Test (FOBT) is one of the diagnostic modali

44 ns age 50 to 75 years with an abnormal fecal occult blood test (FOBT) or fecal immunochemical test (F

45 creening by fecal DNA testing (F-DNA), fecal occult blood testing (FOBT) and/or sigmoidoscopy, or col

46 d mammography, Papanicolaou tests, and fecal occult blood testing (FOBT) but not colonoscopy, flexibl

47 per year of life saved), using annual fecal occult blood testing (FOBT) combined with flexible sigmo

48 lonoscopy or sigmoidoscopy (year 1) or fecal occult blood testing (FOBT) in year 1 and FOBT, colonosc

49 opy plus either sensitive unrehydrated fecal occult blood testing (FOBT) or fecal immunochemical test

50 gy for white men was annual rehydrated fecal occult blood testing (FOBT) plus sigmoidoscopy (followed

51 ikely to have negative attitudes about fecal occult blood testing (FOBT), but not about flexible sigm

52 f once-only flexible sigmoidoscopy and fecal occult blood testing (FOBT).

53 orectal cancer by use of guaiac-based faecal occult blood tests (FOBT) reduces disease-specific morta

54 Screening Programme (asymptomatic but faecal occult blood testing [FOBt] positive).

55 Rates of patient completion of fecal occult blood tests (FOBTs) are often low.

56 Consecutive rounds of fecal occult blood tests (FOBTs) are used to screen for colore

57 Fecal occult blood tests (FOBTs), flexible sigmoidoscopy, or c

58 creened population within 1 year using fecal occult blood testing followed by diagnostic colonoscopy

59 The Se of the occult blood test for CRC detection was calculated to be

60 ained fecal suspensions were used to perform occult blood tests for GI cancer screening and for micro

61 , with less invasive tests (sigmoidoscopy or occult blood tests) for lower-risk persons and colonosco

62 cohort study of routine screening with fecal occult blood testing found a 14% decrease in CRC mortali

63 Annual or biennial guaiac fecal occult blood test (gFOBT) vs no screening (5 trials, n =

64 on screening every 3 years plus annual fecal occult blood testing had an ICER of more than $100,000 p

65 3 years, or every 5 years with annual fecal occult blood testing, had an ICER of less than $55,600 p

66 When used for screening, fecal occult blood tests have positive results about 1% to 16%

67 the results of tests for inflammation (stool occult blood testing [Hemoccult], fecal leukocytes, feca

68 A set of three fecal occult-blood tests--Hemoccult II; Hemoccult II Sensa, a

69 1.38; 95% CI: 1.31, 1.45) but not with fecal occult blood test (HR, 1.00; 95% CI: 0.91, 1.10) than th

70 confidence interval (CI): 1.17, 2.19), fecal occult blood tests (HR=1.31, 95% CI: 1.12, 1.53), screen

71 years, annual highly sensitive guaiac fecal occult blood testing (HSFOBT), annual fecal immunochemic

72 tal tests was defined by a record of a fecal occult blood test in the past 2 years, flexible sigmoido

73 istory of colon cancer and had not had fecal occult blood testing in the past year or flexible sigmoi

74 in stool samples with the Hemoccult II fecal occult-blood test in average-risk, asymptomatic persons

75 nformation that can be used to perform fecal occult blood tests, interpret the results of those tests

76 colorectal cancer (CRC) by the guaiac fecal occult blood test, interval cancers develop in 48% to 55

77 Fecal occult blood testing is a popular screening test because

78 If occult blood testing is done, clinicians must decide how

79 Although fecal occult-blood testing is the only available noninvasive s

80 positives and high false negatives of fecal occult blood testing lead to high costs and low cost-eff

81 f biennial screening with guaiac-based fecal occult blood testing (n = 419,966) showed reduced CRC-sp

82 The effect of screening with fecal occult-blood testing on colorectal-cancer mortality pers

83 early cancer include sensitive guaiac fecal occult blood test or fecal immunochemical test.

84 Consecutive patients with a positive faecal occult blood test or previous adenomas undergoing survei

85 cancer was detected by screening using fecal occult blood testing or evaluation of symptoms.

86 Fecal occult blood testing or flexible sigmoidoscopy was order

87 Screening for colorectal cancer with fecal occult blood tests or sigmoidoscopy can reduce mortality

88 ices Task Force endorse screening with fecal occult blood tests or sigmoidoscopy.

89 165.19), or having undergone a recent fecal occult blood test (OR, 13.69; 95% CI: 3.66, 51.29).

90 diagnostic yield supported the use of fecal occult blood testing plus sigmoidoscopy.

91 nsitivity of one-time screening with a fecal occult-blood test plus sigmoidoscopy.

92 55 years in addition to the biennial faecal occult blood testing programme offered to all individual

93 In randomized trials, fecal occult-blood testing reduces mortality from colorectal c

94 agnostic indications, such as positive fecal occult blood test result (OR, 0.33; 95% CI, 0.19-0.57),

95 ies, these guidelines recommend annual fecal occult blood test screening plus periodic flexible sigmo

96 assing the first screening round of a faecal occult blood test screening programme in a single geogra

97 persons who have positive results on a fecal occult blood test should have a full colonic examination

98 g have illustrated efficacy, including fecal occult blood testing, sigmoidoscopy and colonoscopy.

99 A number of screening tests, including fecal occult blood tests, sigmoidoscopy, double-contrast bariu

100 The use of either annual or biennial fecal occult-blood testing significantly reduces the incidence

101 underwent comprehensive screening with stool occult blood testing, standard upper gastrointestinal en

102 ography colonography, the guaiac-based fecal occult blood test, the fecal immunochemical test, the mu

103 se a positive reaction on guaiac-based fecal occult-blood tests, the relative frequency of upper gast

104 lonoscopy, flexible sigmoidoscopy, and fecal occult blood test were 27.9, 0.6, and 29.5 per 1000 pers

105 cards from three consecutive days for fecal occult-blood testing, which were rehydrated for interpre

106 In a group of patients with positive fecal occult-blood tests who were referred for further evaluat

107 t age 65) or the combination of annual fecal occult blood testing with sigmoidoscopy every 5 years ar

108 One-time screening with both a fecal occult-blood test with rehydration and sigmoidoscopy fai